New Zealand markets open in 1 hour 8 minutes
  • NZX 50

    11,137.88
    -19.78 (-0.18%)
     
  • NZD/USD

    0.6362
    +0.0052 (+0.82%)
     
  • ALL ORDS

    7,350.60
    +24.40 (+0.33%)
     
  • OIL

    113.15
    -1.05 (-0.92%)
     
  • GOLD

    1,813.10
    -0.90 (-0.05%)
     

Should GlaxoSmithKline Have Accepted Unilever's $68 Billion Consumer Health Offer?

·3-min read

In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer. Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting